Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 800 results for "eisai"

MHRA brings Japanese pharma group to Europe

The Medicines and Healthcare products Regulatory Agency (MHRA) has helped Eisai, a Japanese pharmaceutical company, to develop its first European site. MHRA advised on the regulatory requirements Eisai needed for the concepts and design ... European Pharmaceutical Manufacturer, 5 hours ago

16 images for eisai

Asian Scientist, 1 day ago
Pharma Letter, 1 week ago
BioSpace, 1 week ago
Bio Spectrum Asia, 10 hours ago
One News Page United Kingdom, 2 weeks ago
FiercePharma, 1 week ago
BioSpace, 1 week ago
PR Newswire, 1 week ago
Stock Nod, 1 week ago
PR Newswire, 1 week ago

Eisai Co 9-Mos Net Y36.69B Vs Net Y27.76B

Eisai Co. (4523.TO) Tokyo Ended December 31 GROUP 2014 2013 Revenue Y408.48 bln Y445.14 bln Operating Profit 23.83 bln 45.12 bln Pretax Profit 21.66 bln 42.16 bln Net ...
 iMarketReports15 hours ago Eisai's Phase II Trial of Anticancer Agent Lenvatinib in Renal Cell Carcinoma Meets Primary Endpoint  BizWire Express7 hours ago Eisai and Ajinomoto Pharmaceuticals Launch Branched-Chain Amino Acid Formula Livamin Oral Granules in The Philippines  Sys-Con Australia4 days ago EISAI : AND AJINOMOTO PHARMACEUTICALS LAUNCH BRANCHED-CHAIN AMINO ACID FORMULA LIVAMIN ORAL GRANULES IN THE PHILIPPINES  4 Traders3 days ago
[x]  
Pharma Letter

Considerable Additional Benefit of Eisai's Halaven(R) (eribulin) Confirmed by German Federal Joint Committee (G-BA)

/PRNewswire/ -- German Federal Joint Committee decision supports the needs of women with advanced breast cancer in Germany The German Federal Joint Committee (G-BA) today has confirmed that the largest defined patient group has "considerable" ...
 Individual.com1 week ago German Federal Joint Committee confirms 'considerable' benefit of Eisai's Halaven in breast cancer  Pharma Letter1 week ago
[x]  

APAC Epilepsy Therapeutics Market 2015-2019 with Eisai, GlaxoSmithKline, Pfizer & UCB Dominating

Research and Markets (http://www.researchandmarkets.com/research/fl5lm2/epilepsy) has announced the addition of the "Epilepsy Therapeutics Market in the APAC Region 2015-2019" report to their offering. The analysts forecast the Epilepsy Therapeutics ...
 Individual.com2 weeks ago Research and Markets: APAC Epilepsy Therapeutics Market 2015-2019 with Eisai, GlaxoSmithKline, Pfizer & UCB Dominating  TMC Net2 weeks ago Research and Markets: Lung Cancer Clinical Trial Overview 2014  Street Sweeper1 week ago Lung Cancer Clinical Trial Overview 2014  Individual.com6 days ago
[x]  

Eisai Aghast at NHS England Decision to Remove Life Extending Breast Cancer Treatment From Cancer Drugs …

/PRNewswire/ -- NHS England's arbitrary decision causes huge uncertainty for both patients and doctors NHS England was today fiercely criticised by Eisai for the arbitrary process that has led to one of the lowest priced cancer treatments on ...
 Yahoo! Finance2 weeks ago
[x]  
Asian Scientist

Eisai Launches Liver Cirrhosis Drug In The Philippines

The drug for treating liver cirrhosis-associated hypoalbuminemia is also awaiting clinical trials in China. Asian Scientist Newsroom | January 29, 2015 | Pharma AsianScientist (Jan. 29, 2015) - Eisai Co., Ltd. and Ajinomoto Pharmaceuticals ...
 Asian Scientist1 day ago Eisai, Ajinomoto launch Livamin oral granules in Philippines  Pharmaceutical Business Review3 days ago Eisai launches liver cirrhosis in the Philippines  Bio Spectrum Asia10 hours ago EISAI : Ajinomoto launch Livamin oral granules in Philippines  4 Traders2 days ago
FiercePharma

Eisai's copay offer on Belviq has unintended consequences for Arena

As competition in the obesity drug space ramps up, Arena's ($ARNA) marketing partner Eisai is rolling out a new savings card for weight-loss drug Belviq. And for the California drugmaker, that means good news and bad news for its revenue outlook. ...
 FiercePharma1 week ago Arena Pharmaceuticals Reports on Eisai's New Marketing Initiatives for BELVIQ lorcaserin HCl CIV  Pharmacy Choice1 week ago ARENA PHARMACEUTICALS : Reports on Eisai's New Marketing Initiatives for BELVIQ® lorcaserin HCl CIV  4 Traders2 weeks ago Arena Pharmaceuticals, Inc. Reports On Eisai Inc.'s New Marketing Initiatives For BELVIQ?? (lorcaserin HCl) CIV  BioSpace3 weeks ago
[x]  
BioSpace

Eisai Launches New Savings Card to Increase Access and Affordability of BELVIQ® (lorcaserin HCl) CIV

WOODCLIFF LAKE, N.J. BELVIQ is used along with a reduced-calorie diet and increased physical activity for chronic weight management in adults who have a body mass index (BMI) of 30 kg/m2 "We are pleased to see that more and more insurance ...
 Wall Street Select1 week ago Eisai Inc. Launches New Savings Card To Increase Access And Affordability Of BELVIQ?? (lorcaserin HCl) CIV  BioSpace1 week ago
[x]  

Investigators at Eisai Describe Findings in Amino Acids (Involvement of the strychnine-sensitive glycine receptor in the anxiolytic effects of GlyT1...

 4 Traders1 day ago
Pharma Letter

Eisai launches epilepsy treatment Exalief in Russia

Japanese drug major Eisai (TYO: 4523) has announced that epilepsy drug Exalief(eslicarbazepine acetate) will soon be available inRussia. Exalief is also marketed under the trade name Zebinix inEurope, where it is indicated as adjunctive therapy ...
 Pharma Letter1 week ago Exalief (Eslicarbazepine Acetate) Soon to be Available in Russia as a Once Daily Adjunctive Treatment of Partial Onset Seizures in Adults  Individual.com1 week ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less